TICKERNERD
Menu
BIIBBIIBHealthcare · Drug Manufacturers - General

BIIB Stock Forecast: Biogen, Inc. Price Predictions for 2026-2027

Last close, 28 Oct 2026
$244
−3.43% on the day

The 35 Wall Street analysts covering Biogen, Inc. hold a median 12-month price target of $247 — +1.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 76 of 100 as at 28 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$37.3B
Ticker Nerd rank
76/ 100
Median analyst target
$247
Analysts covering
35
Revenue$2.7B+3.4% y/y
Operating income$482.8M
Net income$97.5M
Free cash flow$308.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.3%
1M
+6.7%
YTD
+38.7%
1Y
+63.6%
From 52W high
−3.9%
From 52W low
+65.1%
$148
$254
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BIIB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Biogen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
76/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
99
Volatility
98
Momentum
92
Quality
82
Accruals
63
Revisions
61
Growth
40
Issuance
35
Size
6

Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (35): The company has been issuing shares or taking on financing, diluting existing holders.

Size (6): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

BIIB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BIIB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$150$200$250$300Jan 26Apr 26Jul 26Oct 26BIIBHigh $310Median $247Low $175

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says35 analysts
23 Buy11 Hold1 Sell
Low $175Median $247High $310

The green dot is the last close — the median target sits +1.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
22 Oct 2026B of A SecuritiesMaintainsNeutral$219 → $244
21 Oct 2026TD CowenMaintainsBuy$225 → $250
20 Oct 2026Wells FargoMaintainsOverweight$250 → $310
12 Oct 2026JP MorganUpgradeOverweight$210 → $300
12 Oct 2026JP MorganUpgradeOverweight—
9 Oct 2026UBSMaintainsBuy$240 → $270
9 Oct 2026UBSMaintainsBuy—
8 Oct 2026RBC CapitalMaintainsOutperform$260 → $256
8 Oct 2026RBC CapitalMaintainsOutperform—
10 Sept 2026HSBCMaintainsReduce$165 → $175
10 Sept 2026HSBCMaintainsReduce—
3 Sept 2026Piper SandlerReiteratesOverweight$225 → $245
3 Sept 2026Piper SandlerReiteratesOverweight—
25 Aug 2026RBC CapitalMaintainsOutperform—
25 Aug 2026RBC CapitalMaintainsOutperform$240 → $260
13 Aug 2026Wolfe ResearchUpgradeOutperform$300
13 Aug 2026Wolfe ResearchUpgradeOutperform—
4 Aug 2026MizuhoMaintainsOutperform—
4 Aug 2026MizuhoMaintainsOutperform$221 → $241
3 Aug 2026CitigroupMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

BIIB appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

BIIB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 28 Oct 2026, Biogen, Inc. returned +63.6% against +13.6% for the S&P 500, dividends included.

BIIB vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180Jan 26Apr 26Jul 26Oct 26BIIBS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BIIB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+4.0%
Analysts raising
2
Analysts cutting
3
Fundamentals

Biogen, Inc. (BIIB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
43.5×

Cheaper than 17% of US stocks

Price / sales
3.6×

Cheaper than 33% of US stocks

Price / book
1.9×

Cheaper than 44% of US stocks

EV / EBITDA
13.2×

Cheaper than 27% of US stocks

Growth & margins
Revenue growth (YoY)
3.4%

Higher than 36% of US stocks

Earnings growth (YoY)
−84.6%

Higher than 4% of US stocks

Gross margin
71.6%

Higher than 84% of US stocks

Operating margin
25.1%

Higher than 84% of US stocks

Net margin
8.3%

Higher than 66% of US stocks

Returns & dividend
Return on equity
4.6%

Higher than 53% of US stocks

Return on assets
5.2%

Higher than 78% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Biogen, Inc. (BIIB) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Biogen, Inc. has a market value of $37.3B and an enterprise value of $44.4B.

  • Revenue in the twelve months to 30 June 2026: $10.0B. The latest quarter grew 3.4% year on year.

  • Net income over the same four quarters: $834.6M, a 8.3% net margin.

  • Diluted earnings per share, trailing twelve months: $5.65.

  • Free cash flow in the twelve months to 30 June 2026: $2.5B.

  • Shares outstanding: 147.7M.

  • Trailing P/E: 43.5×; forward P/E: 14.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Biogen, Inc. employs 7,500 people — $1.3M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 29 Oct 2026

Data provided by Twelve Data

Peers

BIIB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
BIIBBiogen, Inc.$37.3B76
BMYBristol Myers Squibb Co.$123.3B94
PFEPfizer Inc.$167.4B82
GILDGilead Sciences, Inc.$197.6B97
AMGNAmgen, Inc.$243.6B94
MRKMerck & Co., Inc.$349.8B79
OGNOrganon & Co.$3.6B77

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Biogen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BIIB news & analysis

Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026

GlobeNewsWire · 29 Oct 2026positive

Biogen announced it will present new Alzheimer’s disease portfolio data at the CTAD Conference on November 16–19, 2026. Topics include CELIA study results for diranersen and long-term, real-world, and treatment-administration analyses for lecanemab.

Why it matters — The presentations will provide updates on Biogen’s Alzheimer’s programs, including clinical and real-world evidence and investigational approaches.

Biogen Q3 Earnings Call Highlights

MarketBeat · 28 Oct 2026positive

Biogen reported third-quarter 2026 revenue growth of 11% year over year, supported by its Apellis acquisition and continued expansion of its growth-product portfolio. Management said it remains on track to return to top-line growth in 2026 and raised the lower end of its full-year non-GAAP diluted EPS guidance.

Why it matters — The update highlights reported revenue growth and a higher floor for full-year earnings guidance, alongside management’s stated 2026 growth outlook.

Biogen Inc. (BIIB) Q3 2026 Earnings Call Transcript

Seeking Alpha · 28 Oct 2026neutral

Biogen held its Q3 2026 earnings call on October 28, 2026, with remarks from company executives and a question-and-answer session involving analysts. The provided excerpt lists participants but gives no financial results or substantive discussion.

Why it matters — The excerpt confirms the earnings call took place, but does not provide details that would indicate its implications for BIIB.

BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened

Zacks Investment Research · 28 Oct 2026neutral

Biogen reported Q3 earnings and revenue above estimates, with growth drugs driving sales. The company tightened its 2026 adjusted EPS outlook amid rising costs.

Why it matters — BIIB watchers may note the stronger-than-estimated quarter alongside a tighter 2026 adjusted EPS outlook and rising costs.

Big Day for Econ Data, Hyperscaler Earnings

Zacks Investment Research · 28 Oct 2026neutral

Zacks Investment Research noted a slate of earnings reports and economic-growth updates for the day.

Why it matters — The excerpt provides no Biogen-specific information, so it offers no direct update for BIIB watchers.

FAQ

Frequently asked questions about BIIB stock

What is the BIIB stock price forecast for 2026-2027?

The 35 Wall Street analysts covering Biogen, Inc. have a median 12-month price target of $247, with estimates ranging from $175 to $310. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BIIB stock a buy right now?

Of the 35 analysts covering Biogen, Inc., 23 rate it a Buy, 11 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Biogen, Inc. 76 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BIIB?

As at 28 Oct 2026, Biogen, Inc. ranks 76 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).

Will BIIB stock go up?

No one can know that. What the data says: the median 12-month target from 35 analysts implies +1.0% from the last close, and Ticker Nerd's factor model ranks Biogen, Inc. 76 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BIIB stock forecast for 2030?

No analyst covering Biogen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BIIB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $175 to $310 over the next 12 months.

How has BIIB stock performed over the past year?

Biogen, Inc. returned +63.6% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Biogen, Inc. do?

Biogen Inc. is a biotechnology company focused on discovering, developing, and delivering therapies for serious neurological, neurodegenerative, and rare diseases.

What is the latest news on BIIB?

The most recent item we track (GlobeNewsWire, 29 Oct 2026): "Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026". Biogen announced it will present new Alzheimer’s disease portfolio data at the CTAD Conference on November 16–19, 2026. Topics include CELIA study results for diranersen and long-term, real-world, and treatment-administration analyses for lecanemab.

Company

About Biogen, Inc.

Biogen Inc. is a biotechnology company focused on discovering, developing, and delivering therapies for serious neurological, neurodegenerative, and rare diseases. Biogen’s current portfolio includes treatments for multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis, and Friedreich’s ataxia, along with therapies and biosimilars used in specialized immunology and related areas. The company also advances medicines through its research and development programs, with a strong emphasis on neuroscience and immunology. Based in Cambridge, Massachusetts, Biogen serves patients and healthcare providers across multiple global markets through its commercial products and collaborations. Its role in the financial market is shaped by its concentration in specialty biopharmaceuticals, recurring demand for chronic-disease treatments, and continued activity in pipeline development and product commercialization.

CEO Mr. Christopher A. Viehbacher · 7,500 employees · United States · https://www.biogen.com